Free Trial
TSE:RVX

Resverlogix 4/1/2024 Earnings Report

Resverlogix logo
C$0.10 +0.01 (+11.11%)
As of 08/1/2025 03:54 PM Eastern

Resverlogix EPS Results

Actual EPS
-C$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Resverlogix Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Resverlogix Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Resverlogix Earnings Headlines

One stock to replace Nvidia
I'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce competitors, dethroning the AI Chip King. But there's a critical component that AI data centers need just as badly as chips. The demand is so massive that a single data center uses enough of it to stretch around the earth eight times. While the media hypes up AI chips, the smart money has found the next big thing. Discover Futurist Eric Fry's "Nvidia-killer" stock ideas.
See More Resverlogix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Resverlogix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Resverlogix and other key companies, straight to your email.

About Resverlogix

Resverlogix (TSE:RVX) Corp clinical-stage biotechnology company. The company is developing an advanced epigenetic drug called apabetalone for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, orphan diseases, and neurodegenerative diseases.

View Resverlogix Profile

More Earnings Resources from MarketBeat